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A B S T R A C T
We report on 109 patients with hemophagocytic lymphohistiocytosis (HLH) undergoing 126 procedures of
allogeneic hematopoietic stem cell transplantation (HSCT) between 2000 and 2014 in centers associated with
the Italian Pediatric Hematology Oncology Association. Genetic diagnosis was FHL2 (32%), FHL3 (33%), or other
defined disorders known to cause HLH (15%); in the remaining patients no genetic abnormality was found.
Donor for first transplant was an HLA-matched sibling for 25 patients (23%), an unrelated donor for 73 (67%),
and an HLA-partially matched family donor for 11 children (10%). Conditioning regimen was busulfan-based
for 61 patients (56%), treosulfan-based for 21 (20%), and fludarabine-based for 26 children (24%). The 5-year
probabilities of overall survival (OS) and event-free survival (EFS) were 71% and 60%, respectively. Twenty-
six patients (24%) died due to transplant-related causes, whereas 14 (13%) and 10 (9%) patients experienced
graft rejection and/or relapse, respectively. Twelve of 14 children given a second HSCT after graft failure/
relapse are alive and disease-free. Use of HLA-partially matched family donors was associated with higher
risk of graft failure and thus with lower EFS (but not with lower OS) in multivariable analysis. Active disease
at transplantation did not significantly affect prognosis. These data confirm that HSCT can cure most HLH pa-
tients, active disease not precluding successful transplantation. Because in HLH patients HLA-haploidentical
HSCT performed through CD34+ cell positive selection was found to be associated with poor sustained en-
graftment of donor cells, innovative approaches able to guarantee a more robust engraftment are warranted
in patients given this type of allograft.
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INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a life-
threatening, hyperinflammatory syndrome characterized by
cytopenia, fever, hepatosplenomegaly, coagulation disor-
ders, and multiorgan dysfunction. It affects children and
adolescents with a higher incidence in the first years of life.
HLH can be triggered by infection, autoimmune disease, or
cancer. In one-third of cases primary immune deficiency re-
sulting in impaired killing of infected cells by T cells or natural
killer cells is present (familial HLH [fHLH]) [1]. The genetic
defect underlying fHLH results in impaired formation and
release of cytotoxic granules and is caused by genes direct-
ly implicated in the secretory lysosome-dependent exocytosis
pathway (PRF1 in FHL2, UNC13D in FHL3, STX11 in FHL4,
STXBP2 in FHL5) [2]. HLH can also be part of clinical syn-
dromeswith other associatedmanifestations, such as Chédiak-
Higashi syndrome, Griscelli syndrome type 2, Hermansky-
Pudlak syndrome type 2, and X-linked lymphoproliferative
disease types 1 and 2 [3]. Approximately 70% of fHLH in
Southern Europe is caused by PRF1 and UNC13D mutations
[4].
Chemoimmunotherapy with dexamethasone, etoposide,
and cyclosporine A can control the inflammatory manifes-
tation in around 60% to 80% of the cases [5-7]. However, in
patients with familial/genetic, relapsing, or severe and
persistent disease, allogeneic hematopoietic stem cell
transplantation (HSCT) is the only established curative treat-
ment [8].
HSCT in a patient with HLHwas first reported in 1986, and
many case series have since then been described [9]. Signif-
icant transplant-related mortality (TRM) was reported in
earlier experiences, with an overall survival (OS) ranging
between 45% and 65% [10-12]. This observation has prompted
the use of conditioning regimens less toxic than the tradi-
tional busulfan-based myeloablative regimen. The use of
fludarabine or treosulfan permitted to gradually reduce TRM
with better outcomes [13,14]. The major drawbacks related
to the use of less toxic regimens are a relevant incidence of
mixed chimerism and overt rejection [15,16]. In this study
we present the outcomes of a cohort of 109 patients affect-
ed by HLH who underwent HSCT in centers affiliated with
the Italian Paediatric Haematology Oncology Association
(AIEOP) network between 2000 and 2014.
METHODS
In this study we collected data reported to the AIEOP Stem Cell Trans-
plantation Registry and selected patients according to all the following criteria:
(1) diagnosis of fHLH, a genetic disorder predisposing to HLH, or clinical HLH
without genetic markers not responding to chemoimmunotherapy treat-
ment or relapsing after treatment [17]; (2) HSCT performed in 1 of the centers
participating in the AIEOP network; and (3) transplantation date between
January 1, 2000 and December 31, 2014. Whenever indicated, the centers
were contacted for further information about patient status before HSCT,
details of the procedure, and outcomes. We excluded patients without ad-
equate data available. Forty-two patients included in this cohort (38.5% of
the overall population) have been previously reported [18].
Patients or their legal guardians signed written informed consent for
collection, analysis, and publication of relevant data. Genetic diagnosis was
centrally performed at Meyer Children Hospital, Firenze, Italy, as previ-
ously described [1].
Central nervous system (CNS) involvement was considered present if a
patient had any of the following findings: elevated cerebrospinal fluid (CSF)
WBC count, clinical symptoms consistent with CNS involvement (ie, sei-
zures or focal or global neurologic deficit), or magnetic resonance imaging
abnormalities consistent with CNS involvement. Patient status before HSCT
was defined according to the following criteria: complete response, nor-
malization of all diagnostic clinical and laboratory abnormalities associated
with HLH; partial response, sustained normalization of 3 or more of the di-
agnostic parameters previously validated [17] and no apparent progression
of other parameters; and nonresponse, normalization of 2 or less diagnos-
tic parameters or clear progression of other aspects of HLH disease.
After HSCT, disease relapsewas defined as recurrence of symptoms typical
of HLH with re-establishment of recipient hematopoiesis. Rejection was
defined as immunologically mediated graft failure.
Definitions and Statistical Analysis
Primary endpoint was event-free survival (EFS), defined as the proba-
bility of being alive and in continuous complete remission (CR) at last follow-
up. To estimate EFS probability death from any cause, relapse, and graft failure
(whichever occurred first) were considered events. Occurrence of stablemixed
chimerismwithout signs and symptoms of HLHwas not considered an event.
Full donor chimerism was defined as presence ≥ 95% leukocytes of donor
origin in peripheral blood or bone marrow. Secondary endpoints were OS,
time to neutrophil and platelet recovery, incidence of relapse, TRM, and acute
and chronic graft-versus-host disease (aGVHD and cGVHD). Probabilities were
calculated from date of transplantation until the event or last follow-up.
Neutrophil engraftment was defined as achieving an absolute neutro-
phil count ≥ .5 × 109/L for 3 consecutive days with no evidence of autologous
recovery (ie, <5% leukocytes of donor origin in peripheral blood or marrow).
Platelet engraftment was defined as achieving a platelet count ≥20 × 109/L
unsupported through platelet transfusions for 7 days. aGVHD occurrence was
evaluated in all patients, whereas cGVHDwas evaluated only in patients sur-
viving beyond day +100 after HSCT. aGVHD and cGVHDwere graded according
to previously published criteria [19,20].
Quantitative variables were reported as median value and range, whereas
categorical variables were expressed as absolute value and percentage. Prob-
abilities of EFS and OS were calculated using the Kaplan-Meier estimates.
Cumulative incidence functions were used to estimate incidence of relapse
and TRM in a competing risks setting, because death and relapse compete
with each other. To estimate aGVHD and cGVHD incidences, relapse and death
were considered as competing events.
A comparison with 2-sided P < .05 was considered to be statistically sig-
nificant. Variables reaching P < .10 in univariate analysis for EFS estimations
were reported in detail and included in Cox proportional hazard regres-
sion models using a backward stepwise selection. Statistical analysis was
performed using NCSS 10 statistical software (2015; NCSS, LLC., Kaysville,
UT [www.ncss.com/software/ncss]) and R 2.5.0 software package
(http://www.R-project.org) [21,22]. Analysis used January 31, 2016 as the
reference date.
RESULTS
Patient Population
One hundred twelve patients with HLH who underwent
129 transplant procedures were reported the AIEOP HSCT reg-
istry. Three patients were not assessable for this study due
to lack of data; thus, the final analysis included 109 pa-
tients and 126 transplant procedures performed in 16 AIEOP
centers. Sixty-five patients (60%) were males and 44 (40%)
were females. Median age at diagnosis was 1 year (range, 27
days to 18 years), whereas median age at first transplanta-
tion was 2 years (range, 4 months to 20 years). Mean time
interval between diagnosis and first HSCT was 289 days
(range, 26 to 1844). The median time interval between di-
agnosis and transplantation was 160 days (range, 35 to 1844)
for patients with a genetic abnormality known to cause HLH
and 237 days in the remaining patients (range, 26 to 553; not
significant). Patient and HSCT characteristics are summa-
rized in Table 1.
Genetic testingwas performed for 94 of 109 patients (86%).
Mutation of PRF1 was found in 31 patients (32%), of UNC13D
in 32 patients (33%), of STXBP2 in 2 patients (2%), of RAB27A
in 6 patients (6%), of SH2D1A in 5 patients (5%), of BIRC4 in
2 patients (2%), and of LYST in 1 patient (1%). No known gene
abnormality was found in 15 patients. CNS involvement at
diagnosis was recorded for 79 patients (72% of the overall pop-
ulation) and was present in 30 patients (38%): 17 (22%) had
elevated cerebrospinal fluid WBC count, 20 (25%) had clin-
ical symptoms consistent with HLH, and 7 (9%) had magnetic
resonance imaging abnormalities consistent with HLH.
At diagnosis, 9 patients were enrolled in the HLH-94 pro-
tocol [5], 41 patients were enrolled in the HLH-04 trial [7,18],
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3 in the Euro-HIT-HLH trial (EudraCT#2011-002052-14), 4 re-
ceived personalized treatment, 2 patients were transplanted
without any other treatment because of a diagnosis of BIRC4
mutation before developing clinical HLH, and for 48 pa-
tients data on frontline treatment received were not available.
Two patients were treated with an anti-IFN-γ monoclonal
antibody in the context of a clinical trial (EudraCT#2012-
003632-23, NCT01818492) [23]. Multiple intrathecal injections
of methotrexate were used for preventing/treating HLH-
related neurologic involvement.
Transplant Procedure
Ninety-five patients received 1 transplant, whereas 14 re-
ceived more than 1 HSCT because of rejection in 8 patients
or disease relapse in 6 patients (preceded by rejection in 1
case): 2 transplants were performed in 12 cases, whereas 3
and 4 transplants were performed in 1 case each. Twenty-
seven HSCT were performed between 2000 and 2004, 36
between 2005 and 2009, and 46 between 2010 and 2014.
Disease status at first HSCT was known for 102 of 109 pa-
tients (94%); 71 patients had active disease (no response, 54;
partial response, 17), 24 were in first CR, and 5 were in later
CR. Two patients received HSCT due to diagnosis of BIRC4 mu-
tation before developing clinical HLH and were analyzed
together with patients in CR. Conditioning regimen was
busulfan-based for 61 patients, treosulfan-based for 21 pa-
tients, fludarabine-based for 26 patients (often in combination
with melphalan), and melphalan-etoposide for 1 patient (for
further details see Tables 1 and 2). Patients given a fludarabine-
based preparation were considered to have received a
reduced-intensity conditioning, whereas those prepared
with either busulfan or treosulfan were allocated to the
myeloablative conditioning regimen group.
The donor for the first transplant was an HLA-matched
sibling donor for 25 patients, an unrelated volunteer se-
lected using high-resolution HLA typing for 73 patients, and
an HLA-partially-matched family donor for 11 patients.
Seventy patients were transplanted with bone marrow–
derived stem cells, 18with peripheral blood stem cells (PBSCs;
mainly used in patients transplanted from an HLA-disparate
relative), and 21 with umbilical cord blood. The mean dose
of mononuclear cells was 6.4 cells × 108/kg for bone marrow
grafts (range, 2.5 to 27.3) and 11.2 cells × 107/kg for cord blood
grafts (range, 2 to 29.2). Themean dose of CD34+ cells for PBSC
grafts was 15.9 cells × 106/kg (range, 2 to 24.8).
Considering the 109 first transplants, GVHD prophylaxis
consisted of cyclosporine A in 25 cases, combination of
cyclosporine A and short-termmethotrexate in 55 cases, and
combination of cyclosporine A and steroids in 20 cases. Post-
transplant high-dose cyclophosphamide was used in 1 case,
whereas in vitro T cell depletion performed through posi-
tive selection of CD34+ cells was used in 8 patients
transplanted from an HLA-mismatched relative.
Engraftment, Chimerism, and GVHD Occurrence
Neutrophil engraftment after first HSCT was obtained in
100 of 109 patients (92%) at a median time of 18 days (range,
9 to 57). Platelet engraftment after first HSCT was obtained
in 87 of 109 patients (80%) at a median interval of 24 days
(range, 9 to 105).
Stable mixed chimerism at time of last evaluation asso-
ciated with good graft function and clinical remission of HLH
was recorded in 6 patients. In these patients, donor contri-
bution to hematopoiesis ranged from 5% to 97%. Fourteen
patients received a second transplant. The reason for second
HSCT was disease relapse (n = 6) or graft failure (n = 8). Sub-
sequent transplants (n = 17, considering also third or fourth
allografts) were performed with busulfan-based (n = 3),
fludarabine-based (n = 5), treosulfan-based (n = 5), or other
conditioning regimens (n = 4). The donor was a matched
sibling donor for 2 procedures, an HLA partially matched
Table 1
Patient and Transplant Characteristics
No. of
Patients
or Median
Percentage
or Range
Gender
Male 65 60
Female 44 40
Genetic diagnosis
FHL2 31 28
FHL3 32 29
Griscelli syndrome 6 5
XLP1 5 5
Other 7 7
No known genetic defect 15 14
Study not performed 13 12
Median age at diagnosis (range) 1 yr (27 days
to 18 yr)
Median age at transplant (range) 2 yr (4 mo
to 20 yr)
CNS involvement
Present 30 28
Absent 49 45
Data not available 30 27
Treatment before transplant
HLH-1994 protocol 9 8
HLH-2004 protocol 41 38
Euro-HIT-HLH protocol 3 3
Other 8 7
Unknown 48 44
Disease status at first transplant
First CR 24 22
More advanced CR 5 5
Partial response 17 16
No response 54 50
Preemptive 2 2
Unknown 7 6
Conditioning regimen
Busulfan-based conditioning 61 56
Busulfan-cyclophosphamide 10 9
Busulfan-etoposide 18 17
Busulfan-fludarabine 6 6
Busulfan-thiotepa 22 20
Other busulfan-based conditioning 5 4
Fludarabine-based conditioning 26 24
Fludarabine-melphalan 12 11
Fludarabine-melphalan-thiotepa 9 8
Other fludarabine-based conditioning 5 5
Treosulfan-based conditioning 21 20
Treosulfan-fludarabine-thiotepa 15 14
Treosulfan-fludarabine 5 4
Treosulfan-fludarabine-
cyclophosphamide
1 1
Other conditioning regimen 1 1
Donor type
Matched sibling donor 25 23
Matched unrelated donor 73 67
HLA partially matched family donor 11 10
Stem cell source
Bone marrow 70 64
PBSCs 18 17
Umbilical blood graft 21 19
Serotherapy
ATG 76 70
Alemtuzumab 7 6
No serotherapy 26 24
T cell depletion
Ex vivo T cell depletion 8 7
ATG indicates antithymocyte globulin.
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family donor for 6 procedures, and an unrelated donor for 9
procedures. Stem cell source was bone marrow or PBSCs in
8 transplants each and cord blood for the remaining allograft.
Neutrophil engraftment after second transplant was ob-
tained in 12 of 14 procedures (86%) at a median time of 17
days (range, 11 to 34). Platelet engraftment occurred at a
median time of 24 days (range, 11 to 55).
Of the 14 patients who received a second transplant, 12
(86%) were alive andwell at last follow-up; however, 1 of them
required 2 further transplant procedures to achieve a good
graft function. One patient died because of viral infection after
the second transplant performed using a different unre-
lated donor, and another (transplanted from an HLA-matched
sibling) died due to respiratory failure after the third
transplant.
aGVHDwas evaluated among the 115 transplants that re-
sulted in donor engraftment. Grades II and III to IV aGVHD
occurred in 29 (25%) and 11 (10%) transplants, respectively.
Among 95 HSCT at risk, cGVHDwas observed in 18 cases (19%)
but was of limited severity in 9 cases (9%) and extensive in
9 cases (9%).
Clinical Outcome
The median observation time for surviving patients was
5.2 years (range, .9 to 14.9), whereas it was 54 days (range,
7 days to 3.8 years) for those who died. At time of the last
follow-up 78 patients (72%) were alive, with a 5-year OS for
the whole study population of 71% (95% confidence inter-
val [CI], 62% to 79%) (Figure 1). There was no difference in
terms of OS according to the type of donor used.
A total of 26 patients (24%) died due to transplant-
related causes at a median of 53 days after HSCT; TRM was
preceded by graft rejection in 4 cases. The cumulative inci-
dence of TRM was 25% (95% CI, 18% to 35%). The number of
fatal events according to the type of conditioning regimen
used is shown in Table 2, whereas Table 3 summarizes the
causes of death of the whole study population; veno-occlusive
disease, lung aspergillosis, and multiorgan failure were the
most frequent causes of death.
Graft failure was observed in 14 patients (13% of the whole
population) at a median of 20 days after HSCT (range, 8 to
51). The cumulative incidence of graft failure was 13% (95%
CI, 8% to 21%). Four of the 14 patients who rejected the
Figure 1. Five-year probability of OS and EFS and cumulative incidence of TRM, rejection, and relapse for 109 patients after the first HSCT.
Table 2
Comparison of Outcome among Busulfan-Based, Treosulfan-Based, and Fludarabine-Based Conditioning Regimens
Busulfan Based
(n = 61)
Treosulfan Based
(n = 21)
Fludarabine Based
(n = 26)
Chi-Square P
Active disease at HSCT 38 (62) 13 (62) 20 (77) N.S.
TRM 16 (26) 3 (14) 7 (26) N.S.
Veno-occlusive disease 4 (7) 0 (0) 3 (11) N.S.
Rejection 7 (11) 1 (5) 6 (22) N.S.
Relapse 4 (7) 2 (10) 4 (15) N.S.
Alive 43 (70) 18 (86) 17 (63) N.S.
Alive and disease-free 37 (61) 15 (71) 14 (52) N.S.
N.S. indicates not significant.
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transplant died due to transplant-related causes (after a
second HSCT in 1 case), whereas 3 subsequently developed
an overt disease recurrence: 2 of them died due to disease
progression and 1 was rescued by a second HSCT. The re-
maining 7 patients who rejected the first transplant are alive
and disease-free after a second transplant.
A disease relapse was observed in 10 patients (9%) at a
median of 163 days after HSCT (range, 41 to 585) and was
preceded by a primary rejection in 3 cases. The cumulative
incidence of relapse was 9% (95% CI, 5% to 17%). Seven of 10
patients who relapsed received a second HSCT; 5 of them are
alive and disease-free.
Sixty-six patients were alive and disease-free after the first
HSCT at time of last follow-up, with a 5-year probability of
EFS of 60% (95% CI, 50% to 69%). Details on univariate anal-
ysis of variables potentially influencing EFS are shown in
Table 4. The variables found to be statistically associated, in
univariate analysis, with EFS were donor type and stem cell
source. Patients transplanted from an HLA partially matched
family donor had a significantly worse EFS (9%; 95% CI, 0%
to 26%) than recipients of a matched family donor trans-
plant (73%; 95% CI, 54% to 92%) or a matched unrelated donor
allograft (63%; 95% CI, 52% to 74%; P < .001) (Figure 2). The
main reason for the lower EFS of patients transplanted from
an HLA partially matched family donor was graft rejection,
which, however, as previously discussed, was largely rescued
by a second allograft. Patients given PBSC transplantation had
a significantly lower EFS probability (39%; 95% CI, 16% to 61%)
as compared with bone marrow recipients (60%; 95% CI, 48%
to 72%) or cord blood recipients (76%; 95% CI, 58% to 94%;
P = .0185). Children who received the transplant within 6
months from diagnosis had a better EFS as compared with
those transplanted later than 6 months from diagnosis (69%
[95% CI, 56% to 81%] versus 50% [95% CI, 37% to 64%]), but
this difference was not statistically significant (P = .069). In
multivariate analysis (Table 5) only the use of a partially
matched family donor confirmed its statistically significant
association with a worse EFS probability, with a relative risk
of 12.26 (95% CI, 2.82% to 53.35%; P = .0008).
DISCUSSION
To the best of our knowledge the cohort of HLH patients
receiving HSCT presented here is the largest ever specifical-
ly analyzed (for a comparative analysis on different outcomes
with previously published cohorts see Table 6). Included were
mainly patients with genetic diagnosis of fHLH. Thirty pa-
tients (28%) without a genetic diagnosis or not molecularly
studied but fulfilling the internationally accepted HLH cri-
teria were transplanted for refractory or relapsed HLH.
Our results confirm that allogeneic HSCT is capable of
curing a large proportion of patients, irrespectively of the
genetic defect responsible for the disease. The optimal timing
for performing HSCT in HLH patients is a matter of debate,
especially in cases with relapsed or refractory disease. In par-
ticular, it is unclear whether for relapsed or refractory disease
aggressive second-line chemoimmunotherapy, aimed at reach-
ing CR before transplant, is warranted. Some case series
suggest that active disease at transplantation might be a risk
factor, especially when an HLA-haploidentical donor is used
[10,12]; however, other data indicate that initial response to
treatment (CR after 2 months of treatment) could be more
informative about the prognosis [11,17,24]. Moreover, in pub-
lished experiences around 30% to 60% of patients have been
transplanted with active disease, indicating that CR is diffi-
cult to obtain in many patients with HLH [11-13,15,17,24].
Our data could shed further light on this issue: Active disease
at transplantationwas not statistically associatedwith adverse
outcomes, whereas, interestingly, patients had a trend for a
worse outcome if the interval between diagnosis and trans-
plantation was longer than 6months. Thus, we speculate that
Table 3
Causes of Death
Number of Transplants Total
First HSCT Subsequent
HSCT
Disease progression 4 1 5
Veno-occlusive disease 7 0 7
Lung aspergillosis 5 0 5
Multiorgan failure 4 1 5
Viral infection (adenovirus/
cytomegalovirus)
3 0 3
cGVHD 2 0 2
aGVHD 1 0 1
Cerebral hemorrhage 0 1 1
Thrombotic microangiopathy 1 0 1
Unknown 1 0 1
Total 28 3 31
Table 4
Univariate Analysis of Factors Influencing EFS
No. of
Patients
No. of
Events
EFS
(%)
95% CI P
All patients 109 43 60 50-69 —
Genetic diagnosis
PRF1 mutation 31 10 67 50-84 N.S.
UNC13D mutation 32 14 55 38-73
Other diagnosis 18 5 72 52-93
No genetic diagnosis 15 7 53 28-79
Study not performed 13 7 45 17-73
CNS involvement at
diagnosis
Present 37 16 57 41-73 N.S.
Absent 72 27 61 49-72
Years of transplant
2000-2004 27 13 52 33-71 N.S.
2005-2009 36 15 58 42-74
2010-2014 46 15 67 54-81
Time from diagnosis
to HSCT
<6 mo 56 17 69 56-81 .0699
≥6 mo 53 26 50 37-64
Disease status
Active disease (no or
partial response)
71 31 56 44-68 N.S.
CR or preemptive 31 10 67 50-84
Missing information 7 2 69 32-100
Conditioning regimen
Busulfan-based 61 24 60 47-72 N.S.
Fludarabine-based 26 13 51 32-70
Treosulfan-based 21 6 70 50-90
Donor
MFD 25 6 73 54-92 <.001
MUD 73 27 63 52-74
PMFD 11 10 9 0-26
Stem cell source
BM 70 27 60 48-72 .0185
PBSCs 18 11 39 16-61
UCB 21 5 76 58-94
No. of HSCTs*
First HSCT 109 43 60 50-69 N.S.
Second HSCT 14 4 71 48-95
Bold type was employed to highlight statistically significant data.
MFD indicatesmatched family donor; MUD,matched unrelated donor; PMFD,
partially matched family donor; BM, bonemarrow; UCB, umbilical cord blood.
* Data were considered for first HSCT only.
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active disease at transplantation could be indicative of more
aggressive disease, potentially not adequately responding even
to additional second-line rescue treatment. If so, the best
frontline therapy should be selected to achieve adequate
disease control, without postponing HSCT at more than 6
months from diagnosis. Treating patients for a longer time
with the scope of obtaining CR before transplantation could
expose to the risk of deterioration of the general status, thus
making the outcome of transplant worse. Whether the use
of novel approach to HLH by immunotherapy, such as that
based on the use of an anti-IFN-γ monoclonal antibody
(EudraCT#2012-003632-23, NCT01818492), may lead to
better rates of CR at time of transplantation in refractory pa-
tients remains to be definitively confirmed [23].
Donor availability plays an important role in decidingwhen
to perform a transplant. Our data indicate that although a
matched sibling donor is the donor of choice, an unrelated
donor selected using high-resolutionmolecular typing of HLA
loci can be usedwith comparable patient’s outcome. Our study
confirms also that the use of umbilical cord blood is a fea-
sible option [17,25]. In particular, 21 patients (19%) who
received a cord blood allograft had outcomes comparable with
those of patients given bone marrow cells. Probably, young
age at HSCT with a consequent favorable ratio of number of
cells infused per kilogram of recipient body weight makes
this kind of proceduremore appropriate for HLH patients than
in other clinical settings.
Our data indicate that, so far, the use of HLA partially
matched family donors is associated with an increased risk
of graft failure, however, largely rescued by a second al-
lograft in line with the data reported in 2 previously published
studies [16,26]. Investigation of new approaches to HLA-
haploidentical transplantation, such as that based on the
infusion of the graft after the selective depletion of TCR αβ-T
cell/CD19+ cells, is urgently needed to improve the rate of sus-
tained donor engraftment and to more confidently offer a
prompt transplant option also to patients lacking a matched
donor [27].
The main causes of death in our cohort were complica-
tions related to HSCT, namely veno-occlusive disease, lung
aspergillosis, and multiorgan failure; HLH relapse only ac-
counted for 5 deaths. Indeed, busulfan-based myeloablative
conditioning for HLH patients has been reported to be asso-
ciated with a high rate of infections, veno-occlusive disease,
and possibly a higher incidence of pulmonary complications
[10-12,28-30]. To overcome these issues, in the mid-2000s
use of fludarabine-melphalan reduced-intensity condition-
ing was introduced, leading to less TRM and better outcome,
although at the expense of higher frequency of mixed chi-
merism, secondarygraft failure, and relapse rates [13,16,31-33].
Excellent results were reported with the use of treosulfan-
based conditioning regimens, which, despite being
myeloablative, seem to be associated with less extramedul-
lary toxicity [14,15]. Our cohort is the only one in which the
3 above conditioning regimens have been used in a signifi-
cant number of patients and outcomes could be directly
compared (Tables 2 and 6). Although no statistically signif-
icant differenceswere observed, a trend toward better OS and
EFS after treosulfan-based conditioning was evident. In our
Figure 2. Five-year probability of EFS according to the type of donor used. MFD indicates matched family donor; MUD, matched unrelated donor; PMFD, HLA
partially matched family donor.
Table 5
Multivariate Analysis of Factors Influencing EFS (Data Were Considered for
First HSCT Only)
Variable Relative
Risk
(95% CI) P
Interval diagnosis, HSCT
>6 mo vs. <6 mo 1.15 .59-2.24 .68
Donor
MUD vs. MFD 2.16 .85-5.49 .11
PMFD vs. MFD 12.26 2.82-53.35 .0008
Stem cell source
Cord blood vs. bone marrow .48 .18-1.28 .14
Peripheral blood vs. bone marrow .63 .21-1.87 .41
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Table 6
Results of Published Cooperative Studies on HSCT in HLH Patients
Author,
period
No. of Patients Conditioning
Regimen
Type of Donor Primary Engraftment OS EFS GVHD Notes
Horne et al.
1995-2000
86 BU/CY/VP-16: 41
Others: 45
MR n = 24
MUD n = 33
HAPLO n = 16
MMUD n = 13
90%
HAPLO 81%
64% ± 10% at 3 years
MR 71% ± 18%
MUD 70% ± 16%
HAPLO 50% ± 24%
MMUD 54% ± 27%
— aGVHD grades II-IV 32%
MR 18%
MUD 30%
HAPLO 36%
MMUD 58%
Graft failure: 3
Disease recurrence: 3
Sawada et al.
1990-2009
53 MAC: 37
(BU/CY/VP-16: 23)
RIC: 16
MR n = 7
MMR n = 1
MUD n = 20
MMUD (1 loc) n = 18
MMUD (2 loc) n = 7
26/38 of assessable 65.4% ± 6.6% at 2 years 57.6% ± 6.9% at 2 years Not reported
Baker et al.
1989-2005
91 BU/CY/ VP-16 ± ATG: 73
Other 18
MUD n = 54
MMUD (1 loc) n = 32
MMUD (2 loc) n = 4
Neutrophil 85%
Platelet 54%
52% at 1 year
45% at 3 years
(Bu/CY/ VP-16 53%,
Other regimens 19%)
— aGVHD grades II-IV 41%
aGVHD grades III-IV 24%
cGVHD 25%
(OS Bu/CY/ VP-16 53%,
Other regimens 19%)
Yoon et al.
1996-2008
19 BU/CY/ VP-16 ± ATG: 12
FLU-based: 5
Other: 2
MR n = 6
MUD n = 8
MMUD n = 5
16/19 73.3% at 5 years
MR 85.7%
MUD 87.5%
MMUD 40%
— aGVHD grades II-IV 5/16 TRM 21%
Ohga et al.
1995-2005
57
(14EBV-related)
MAC: 43
(Bu/CY/ VP-16: 31)
RIC: 14
53 Allogeneic
MR n = 8
MUD n = 24
HAPLO n = 4
MMUD n = 17 (UCB)
29/42 HLH
7/11 EBV-HLH
HLH 65% ± 7.9%
EBV-HLH 85.7% ± 9.4%
at 10 years
— Not reported TRM 11/42 in the HLH group
Messina et al.
2000-2014
109 BU-based: 61
TREO-based: 21
FLU-based: 26
MR n = 25
MUD n = 73
HAPLO n = 11
Neutrophil 92%
Platelet 80%
71% at 5 years EFS 60% at 5 years
MR 73%
MUD 63%
HAPLO 9%
aGVHD grades II-IV 29%
aGVHD grades III-IV 11%
cGVHD 18%
TRM 25%
CI graft failure 13%
CI disease recurrence 9%
BU indicates busulfan; CY, cyclophosphamide; VP-16, etoposide; MR, matched related donor; MMUD, mismatched unrelated donor; HAPLO, haploidentical; MAC, myeloablative conditioning; RIC, reduced-intensity condi-
tioning; FLU, fludarabine; UCB, unrelated cord blood; TREO, treosulfan; CI, cumulative incidence.
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experience the high TRM (26%) observed with busulfan was
not significantly different from that recordedwithfludarabine-
based regimens. Moreover, fludarabine-based conditioning
exposed patients to a higher risk of graft failure/relapse and
need of a second transplant (Table 2). On the other hand,
treosulfan-based conditioning resulted in lower TRM (14%)
with acceptable rates of graft failure (5%) or relapse (10%),
this translating into a remarkably high rate of cured pa-
tients. The potential advantages deriving from the use of a
treosulfan-basedmyeloablative conditioning regimensmust
be confirmed in properly designed, prospective randomized
trials to be conducted in HLH patients.
Importantly, patients receiving a second transplant did not
have worse outcomes than patients transplanted only once.
This finding suggests that a second allograft may be safely
offered to HLH patients in case of relapse or rejection, pro-
vided they did not develop significant end-organ damage due
to either HLH itself or the first HSCT. In line with our data, a
recently published study analyzed the outcome of 18 HLH
patients given a second allograft because of HLH recurrence
(10 patients) or low donor chimerism level only (8 patients)
[26]. Ten of these patients were reported to be alive and
disease-free, whereas fatalities were similarly distributed
between patientswith andwithout prior disease recurrence.
Our results on probabilities of 5-year OS and EFS ob-
tained in a larger cohort of unselected children are slightly
better as compared with some other similar cooperative
studies (Table 6) [11,25,29,34,35]. This might be explained by
the higher proportion of patients receiving fludarabine- or
treosulfan-based conditioning in our cohort or by the fact that
we included only patients transplanted after the year 2000.
Themulticenter, retrospectivedesignof our studyhas some
intrinsic limitations, such as lacking information on
pretransplant treatment in a relevant proportion of patients.
Yet it describes well the current practice in HSCT for HLH.
In conclusion, our data indicate that in patients with HLH,
allogeneic HSCT is able to cure two-thirds of patients, re-
storing normal immune response toward pathogens and
abrogating the hyperinflammatory state typical of HLH. HSCT
from an HLA-partially matched relative in patients with HLH
is currently associated with unsatisfactory rate of engraft-
ment, with new approaches needed to ameliorate this
outcome. However, rejection and secondary graft failures are
events that could be salvaged by a second allograft. Active
disease does not preclude the chance of benefiting from trans-
plantation, which should be ideally performed within 6
months from diagnosis. Finally, our data suggest that the use
of treosulfan-based conditioning appears to be an attrac-
tive option to reduce TRM in this fragile population of patients.
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